Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Ministery of Health, Brazil FINEP - Financiadora de Estudos e Projetos |
---|---|
Information provided by: | Ministery of Health, Brazil |
ClinicalTrials.gov Identifier: | NCT00349271 |
The purpose of this study is to determine effect of cell therapy in patients with severe dilated cardiomyopathy
Condition | Intervention | Phase |
---|---|---|
Chagas Cardiomyopathy |
Procedure: Stem cell Drug: Filgrastime (G-CSF) Drug: Standart therapy |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Multicenter Randomized Study Of Cell Therapy In Cardiopathies - Chagas Cardiomyopathy |
Estimated Enrollment: | 300 |
Study Start Date: | January 2006 |
Estimated Study Completion Date: | December 2009 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Stem Cell therapy: Experimental
Stem Cell therapy
|
Procedure: Stem cell
Stem cell
Drug: Filgrastime (G-CSF)
Filgrastime (G-CSF)
|
Standart therapy: Active Comparator
Standart therapy
|
Drug: Standart therapy
All drug with clinical evidence of benefical effect in Chagas disease
|
This protocol describes a double-blind placebo controlled randomized clinical trial to evaluate the efficacy of bone marrow derived stem cell implants in 300 bazillion patients with dilated cardiomyopathy and heart failure in class III or IV of the New York Heart Association.
The primary endpoint of this study is to evaluate the effect of the autologous bone marrow stem cell implant in the increase of the ejection fraction of the left ventricle in comparison with a control group, under optimized therapy for dilated cardiomyopathy. Secondary endpoints will evaluate the alteration in NYHA functional class, mortality rate, physical capacity (by ergoespirometry), life quality (Minnesota questionnaire) and pulmonary congestion in dilated cardiomyopathy patients the received the autologous bone-marrow stem cell implant.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Antonio Carlos C de Carvalho, MD,PhD | +5521-22055422 | acarlos@biof.ufrj.br |
Contact: Bernardo R Tura, MD,MsC | +5521-22055422 | tura@centroin.com.br |
Brazil | |
INCL - National Institute of Cardiology Laranjeiras | Recruiting |
Rio de Janeiro, Brazil, 22.240-006 | |
Contact: Augsuto Z Bozza, MD +5521-2285-3344 ext 2288 abozza@cardiol.br | |
Contact: Helena F Martinho, MD +5521-2285-3344 ext 2288 hfmartino@alternex.com.br | |
Sub-Investigator: Helena F Martino, MD |
Principal Investigator: | Ricardo R Santos, MD,PhD | Centro de pesquisa Gonzalo Muniz |
Principal Investigator: | Gilson Feitosa, MD | Hospital Santa Isabel |
Responsible Party: | National Institute of Cardiology ( Antonio Carlos Campos de Carvalho ) |
Study ID Numbers: | EMRTCC-CHG |
Study First Received: | July 5, 2006 |
Last Updated: | January 15, 2009 |
ClinicalTrials.gov Identifier: | NCT00349271 History of Changes |
Health Authority: | Brazil: Ministry of Health |
Chagas Cardiomyopathy Dilated Cardiomyopathy stem cells Therapeutics Randomized Controlled Trials |
Protozoan Infections Heart Diseases Dilated Cardiomyopathy Chagas Cardiomyopathy Cardiomyopathy, Dilated |
Trypanosomiasis Parasitic Diseases Chagas Disease Cardiomyopathies |
Protozoan Infections Heart Diseases Chagas Cardiomyopathy Trypanosomiasis Cardiovascular Diseases |
Parasitic Diseases Sarcomastigophora Infections Mastigophora Infections Chagas Disease Cardiomyopathies |